cc, page-26

Yes, and one of Keith's questions was right to that point that of the 2 routes to approval and marketing to end user / patient:
1. almost just do the "paperwork" / human factor studies etc for already approved molecules / treatments, in the new preferred Uni WI device
2. as opposed to new drug in new device needs full trial phases II III , taking longer etc.

So route 1. would be simpler and faster with smaller / shorter clinical studies etc.

Looking at today's preso slides, the bar chart on page 12 shows Amgen equal largest with AstraZeneca/MedImmune and Lilly, having 11 molecules in or out of their 'pipelines', and has comments:
"Over 100 phase II, III or marketed molecules from biopharma companies identified as having products with characteristics that make them potential candidates for prospective use with wearable or hand-held injection technologies"

and along-side it there's a pie chart showing 35% of these (ie. >35moecules) have been approved and are currently being marketed. (with Amgen the largest - 7 molecules)
Sure get the feeling Amgen know what they're doing, 'partnering' with Unilife, and yet we won't want to preclude other competitors and molecules coming on board either - hence the ongoing veils of secrecy . .